Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Lifecare ASA Share Issue/Capital Change 2024

Oct 1, 2024

3654_rns_2024-10-01_d402211e-b6a2-4557-82bd-059786ac5fa5.html

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

Lifecare ASA: Ex. consolidation (reverse split) of shares and warrants today

Lifecare ASA: Ex. consolidation (reverse split) of shares and warrants today

Reference is made to the stock exchange announcement made on 27 September 2024

with key information regarding the consolidation (reverse split) of the

Company's shares and the warrants issued by the Company pursuant to a

resolution made by the extraordinary general meeting held on 16 May 2024 (the

"Warrants"). The following information is provided in connection with the ex.

date for the consolidation (reverse split) of shares and Warrants:

Issuer name: Lifecare ASA

Ex. date: 1 October 2024

Type of corporate action: Consolidation (reverse split) of shares and Warrants

This information is published in accordance with the requirements of the

Continuing Obligations.

About Lifecare:

Lifecare is a clinical stage medical sensor company developing technology for

sensing and monitoring of various body analytes. Lifecare's main focus is to

bring the next generation of Continuous Glucose Monitoring ("CGM") systems to

market. Lifecare enables osmotic pressure as sensing principle, combined with

the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR")

on the sensor body for read-out of pressure variations. Lifecare's sensor

technology is referred to as "Sencell" and is suitable for identifying and

monitoring the occurrence of a wide range of analytes and molecules in the

human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, [email protected], +47 40 05 90 40

Renete Kaarvik, CFO, [email protected], +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities

Trading Act, §5-12. The information was submitted for publication at

2024-10-01 07:00 CEST.